Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T96721
|
||||
| Former ID |
TTDS00339
|
||||
| Target Name |
Vascular endothelial growth factor
|
||||
| Synonyms |
VEGF; Vascular endothelial cell growth factor
|
||||
| Target Type |
Successful
|
||||
| Disease | Adult primary hepatocellular carcinoma [ICD10: C22] | ||||
| Breast cancer [ICD9: 174, 175; ICD10: C50] | |||||
| Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
| Lymphoma; Non-hodgkin's lymphoma [ICD9: 200, 202, 202.8; ICD10: C81-C86, C82-C85] | |||||
| Metastatic breast cancer [ICD10: C50] | |||||
| Multiple myeloma [ICD9: 203; ICD10: C90] | |||||
| Non-small cell lung cancer [ICD10: C33-C34] | |||||
| Non-small cell lung cancer; Metastatic colorectal cancer [ICD9:153, 154; ICD10: C33-C34, C18-C21] | |||||
| Recurrent squamous cell carcinoma of the hypopharynx [ICD10: D37] | |||||
| Target Validation |
T96721
|
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Avastin+/-Tarceva | Drug Info | Phase 3 | Non-small cell lung cancer | [1] |
| Bevacizumab + Erlotinib | Drug Info | Phase 3 | Non-small cell lung cancer; Metastatic colorectal cancer | [2], [3] | |
| Bevacizumab + Rituximab | Drug Info | Phase 3 | Lymphoma; Non-hodgkin's lymphoma | [4] | |
| Bevacizumab + Trastuzumab | Drug Info | Phase 3 | Metastatic breast cancer | [5] | |
| Bevacizumab + Erlotinib | Drug Info | Phase 2 | Adult primary hepatocellular carcinoma | [6], [7], [8], [9], [10], [11] | |
| Bevacizumab + Trastuzumab | Drug Info | Phase 2 | Breast cancer | [12] | |
| Bevacizumab + Erlotinib | Drug Info | Phase 1/2 | Recurrent squamous cell carcinoma of the hypopharynx | [13] | |
| AT001/r84 | Drug Info | Phase 1 | Cancer | [14] | |
| Inhibitor | Avastin+/-Tarceva | Drug Info | [15], [16] | ||
| Bevacizumab + Erlotinib | Drug Info | [17] | |||
| Bevacizumab + Rituximab | Drug Info | [17] | |||
| Bevacizumab + Trastuzumab | Drug Info | [17] | |||
| BIBF100 | Drug Info | [18] | |||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of Roche. | ||||
| REF 2 | ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer | ||||
| REF 3 | ClinicalTrials.gov (NCT00598156) Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva | ||||
| REF 4 | ClinicalTrials.gov (NCT00486759) A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma. U.S. National Institutes of Health. | ||||
| REF 5 | AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J Clin Oncol. 2013 May 10;31(14):1719-25. | ||||
| REF 6 | ClinicalTrials.gov (NCT01130519) A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer. U.S. National Institutes of Health. | ||||
| REF 7 | ClinicalTrials.gov (NCT00287222) Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma | ||||
| REF 8 | ClinicalTrials.gov (NCT00365391) Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer | ||||
| REF 9 | ClinicalTrials.gov (NCT02655536) Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial | ||||
| REF 10 | Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S17-23. doi: 10.3816/CLC.2009.s.003. | ||||
| REF 11 | Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011 May 28;377(9780):1846-54. doi: 10.1016/S0140-6736(11)60545-X. | ||||
| REF 12 | ClinicalTrials.gov (NCT00365365) Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer | ||||
| REF 13 | ClinicalTrials.gov (NCT00055913) Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | ||||
| REF 15 | Clinical pipeline report, company report or official report of Genentech (2009). | ||||
| REF 16 | Clinical pipeline report, company report or official report of Genentech (2009). | ||||
| REF 17 | Clinical pipeline report, company report or official report of Roche (2009). | ||||
| REF 18 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.